Efficacy and Safety/Tolerability of Ragweed MATA MPL

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
Ragweed MATAMPL has been developed by Allergy Therapeutics to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting ragweed pollens causing rhinitis and/or conjunctivitis with or without mild to moderate asthma bronchiale. The purpose of this study is to compare the efficacy of Ragweed MATAMPL versus placebo in ragweed-allergic subjects following 4 subcutaneous injections of study medication administered before the start of the 2007 ragweed pollen season
Epistemonikos ID: d41a82695062bc0adf02e5f64dffddd7bab1b50e
First added on: May 04, 2024